Parent Study: A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism Sub-study: A Follow-up Substudy After Completion of the BaxPA Main Study.

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 212 participants.

Also called NCT07007793

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 212 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07007793
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Australia, Canada, China, France, Germany, India, Italy, Japan, Spain, Taiwan, United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT07007793. Randomized; quadruple masking; primary purpose treatment. Start 2025-08-07 (actual); primary completion 2027-07-27 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Parent Study: A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism Sub-study: A Follow-up Substudy After Completion of the BaxPA Main Study.
Acronym
BaxPA
Condition
Primary Hyperaldosteronism
Intervention (Drug)
Baxdrostat
Intervention (Drug)
Placebo
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct07007793
Content hash
7013a20c3bc7efb707daafa3d3c6aff64bfd32a77ff3e9f700e72849424d8978